Introduction
Primary T-cell immunodeficiencies (PIDs) comprise a heterogeneous group of genetic disorders characterized by profound impairment of T-lymphocyte differentiation. [1] [2] [3] This is always associated with a direct or indirect deficiency in B-cell immunity. [1] [2] [3] Consequently, in the absence of treatment, patients are highly susceptible to infections caused by microorganisms within the first year of life. In this context, allogeneic hematopoietic stem-cell transplantation (HSCT) constitutes life-saving therapy and is highly successful when a related, HLA-genoidentical donor is available. 4 However, in many cases, HLA-identical donors are not available and HSCs from a haploidentical donor must be used. In this situation, the bone marrow inoculum must be strictly T-cell depleted in order to prevent lethal graft-versus-host disease (GvHD). Pretransplantation myeloablation may be used to increase the engraftment rate and to improve T-ϩ B-cell immune reconstitution (particularly in natural killer-positive [NK ϩ ] severe combined immunodeficiencies [SCIDs] ), though at the cost of increased early toxicity. [4] [5] [6] [7] [8] [9] T-cell reconstitution and detection of de novo thymopoiesis requires a 3-to 6-month period after haploidentical HSCT. However, there is little published information on the long-term outcomes of HSCT in SCID. Patel et al 10 and Sarzotti et al 11 have shown that within 10 to 12 years, the thymus' ability to support T-cell development fell to zero following haploidentical transplantation in SCID patients. This was based on quantification of TREC ϩ cells, reflecting emigration of newly formed T cells from the thymus. It is unclear whether this decline in thymic function is due to the inability of a SCID patient's hypoplastic thymus to sustain long-term thymopoiesis or whether donor stem-cell engraftment was inadequate (and thus prevented the thymus from being further seeded with progenitor cells for 10 or more years).
Thymic output can be assessed in vivo by surface immunophenotyping of CD45RA ϩ naive T cells in the peripheral blood. However, these cells can proliferate via an antigen-independent pathway and may persist in the circulation for a long time before converting to a memory phenotype. 12 In parallel, many investigators have used the episomal DNA circles generated during rearrangement of gene segments encoding the T-cell receptor (TCR) to monitor thymic function following HSCT. 13 In order to assess post-HSCT thymic output capacity, we monitored T-cell reconstitution in a cohort of 31 PID patients starting 10 years after HSCT, as assessed by determination of TREC levels and CD31 ϩ CD45RA ϩ CD4 ϩ T-cell counts. 14 We also analyzed associated factors that could be able to predict the quality of T-cell reconstitution.
(followed up for Ն 10 years) were evaluated. Patient characteristics are shown in Table 1 . Eleven patients had a ␥c deficiency, 3 had a JAK-3 deficiency, 1 had an IL7-R␣ deficiency, 3 had either a Rag-1 (n ϭ 1) or Rag-2 (n ϭ 2) deficiency, 2 had an Artemis deficiency, 5 had Omenn syndrome (caused by Rag-1 deficiency in 4 cases, with the fifth case undetermined), 2 had molecularly undetermined T Ϫ B Ϫ NK ϩ SCID, 2 had an HLA class II expression deficiency phenotype, and 2 had an undetermined functional T-cell immunodeficiency (T-cell ID).
Eleven patients received an HSC transplant from an HLA-identical donor (with 6 from a genoidentical donor and 5 from a phenoidentical related donor). When patients lacked T cells completely, a nonmanipulated marrow sample was used without a preconditioning regimen. Twenty patients underwent haploidentical HSCT following T-cell depletion in order to prevent GvHD. Seven of the latter individuals received a fully myeloablative conditioning regimen (CR) consisting of busulphan (Bu; a total dose of 16 or 20 mg/kg) and, depending on whether T cells were present, cyclophosphamide (Cy; 200 mg/kg). A second group of 10 patients was conditioned with a lower dose of busulphan (8 mg/kg) in combination with cyclophosphamide (200 mg/kg), in accordance with the European Society for Immunodeficiencies/The European Group for Blood and Marrow Transplantation (ESID/EBMT) guidelines on PID. Bone marrow harvests were depleted of T cells by E-rosetting (n ϭ 13), alemtuzumab antibody treatment (n ϭ 2), or selection of CD34 ϩ cells (n ϭ 5), depending on when HSCT had been performed. Thirteen of the 31 patients had at least grade II acute GvHD (8 with grade II and 5 with grade III). Informed consent for this study was obtained from parents and/or patients, depending on the individual's age, in accordance with the Declaration of Helsinki. The study was approved by the Institutional Review board at the Hospital Necker-Enfants Malades.
Flow-cytometry analysis
Over the period from 2003 to 2005, blood samples were obtained from 31 patients at different time points after HSCT (10 to 27 years). Phenotype analysis of blood lymphocytes was performed using 3-color immunofluorescence flow cytometry. The following conjugated monoclonal antibodies were used: CD3-APC, CD45RA-PE, CD4-FITC or APC, CD8-PE, and CD31-FITC. Data were acquired with a FACSCalibur and analyzed using Cell Quest Software (Becton Dickinson Systems, Heidelberg, Germany). The percentage of CD31 ϩ CD45RA ϩ cells in the CD4 ϩ T-cell population was determined as a guide to the proportion of recent thymic emigrants in the CD4 T-cell subset. 14 We decided not to assess naive CD8 T cells by immunophenotyping, as CD31 cannot be considered to be an unequivocal marker of naive CD8 T cells. Results are presented as absolute counts for each analyzed subset (see "T-cell phenotype determination"). Lymphocyte proliferation was determined by the amount of 3 H-thymidine incorporated into peripheral-blood mononuclear cells (PBMCs) after stimulation with phytohemagglutinin (PHA) or tetanus toxoid (TT), following an appropriate immunization schedule. Each study was run in parallel with samples from healthy adult controls.
Quantitative analyses of thymic function
PBMCs were obtained using Ficoll density gradient centrifugation on a lymphocyte separation medium (Eurobio, Courtaboeuf, France). Signal joint TRECs (sjTRECs; ␦Rec-j␣) were determined using real-time quantitative polymerase chain reaction (PCR), as described previously. 15, 16 The TREC content was expressed as the number of TREC copies per 1 ϫ 10 5 PBMCs. The control value (established by assessing 20 healthy individuals) was between 150 and 2500 copies/1 ϫ 10 5 PBMCs.
Chimerism analysis
CD3 ϩ , CD19 ϩ , and CD15 ϩ populations were isolated by cell sorting (purity, Ͼ 95%). Two methods were used to analyze the chimerism of T and B lymphocytes and monocytes; one method was based on detection of variable number of tandem repeats (VNTR) markers (with a sensitivity of 1%) and the second used fluorescence in situ hybridization (FISH) with PDMX1 Red and pLAY 113.5 green fluorescence probes to detect locus DXZ1 (Xp11.1-q11.1) on the X chromosome and locus DYZ1 (Yq12) on the Y chromosome (with a sensitivity of 5%).
Statistical analysis
Due to the small sample size, we analyzed correlations between TREC values and other continuous variables. Naive CD4 T cells, CD3 ϩ T cells, CD4 ϩ T cells, CD8 ϩ T cells, and mitogen-and antigen-induced proliferation were investigated using Spearman correlation coefficient. Intergroup comparisons of continuous variables (namely host/donor status, busulphan status, and ␥c status) were performed with the Wilcoxon rank sum test or the Kruskal-Wallis test, depending on the number of groups analyzed. Fisher exact test was used to compare categoric variables. A 2-sided P value of .05 or less was considered to indicate statistical significance. Statistical analyses were conducted with R software (a language and environment for statistical computing), version 2.0.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results

T-cell phenotype determination
Absolute counts of CD3, CD4, CD8, and recent thymic emigrants (as defined by naive CD4 T cells expressing CD31) and the results of mitogen-or tetanus toxoid-induced T-cell proliferation are shown in Table 1 . In 26 of the 31 patients, T-cell counts were within the age-matched normal range (0.8 ϫ 10 9 /L to 3.5 ϫ 10 9 /L [800-3500/L]). CD4, CD8, and naive CD31 ϩ CD45RA ϩ CD4 ϩ T-cell counts were within the normal range (0.4 ϫ 10 9 /L to 2. ). T-cell proliferation in response to tetanus toxoid (TT) was also within the normal range (Ͼ 10 000 cpm) in 17 patients and was detectable (Ͼ 5000 cpm) in another 10. These data attest to the persistence of functional naive and memory T cells over a 10-to 27-year period after HSCT.
TREC quantification was used to analyze the population of naive T cells that had not undergone cell division in the periphery. TREC ϩ cell counts were in the normal range in 18 of the 31 patients and were detectable in 2 other individuals. We used a cutoff value of 1 ϫ 10 2 TRECs/10 5 PBMCs to distinguish patients with TREC ϩ cells from those lacking them. The first group consisted of 20 patients (Table 1 ) and the second comprised 11. A very strong correlation was found between TREC ϩ cell numbers and the absolute counts of naive CD31 ϩ CD45RA ϩ CD4 ϩ T cells (Table 1 ; Figure 1 ; r ϭ 0.84; P Ͻ .001).
TREC ؉ naive T cells in patients with donor myeloid chimerism
Several parameters were studied in order to discover possible correlations with the presence of TREC ϩ naive T cells. In order to assess myeloid chimerism, relationships were tested by determining the frequency of donor-derived cells in sorted granulocytes. In all 31 cases, the T-cell population was of donor origin (including those patients who still had host T cells prior to HSCT), whereas B-cell chimerism correlated with myeloid chimerism. This prompted us to split the population with detectable TRECs and naive T cells into 2 subgroups (1A and 1B; Table 1 ) according to their granulocyte chimerism. In 11 of the 20 patients (subgroup 1A), granulocytes were partly or exclusively of donor origin, whereas they were exclusively of host origin in 9 individuals (subgroup 1B), taking into account the method's sensitivity (see "Patients, materials, and methods"). In contrast, no donor granulocytes could be For personal use only. by on December 29, 2009 . www.bloodjournal.org From detected (group 2) in all but 1 patient in whom no TREC ϩ /naive T cells could be detected (n ϭ 11) 10 years or more after HSCT. As shown in Figure 2A , there was a significantly higher mean TREC ϩ level in patients with donor-derived granulocytes than in individuals with host-derived granulocytes (P ϭ .014).
Conversely, the patients lacking donor-derived granulocytes (n ϭ 19) could be separated into 2 groups according to the presence or absence of TREC ϩ T cells (n ϭ 9 and n ϭ 10, respectively; Table 1 ). As expected, detection of donor-derived granulocytes was highly correlated with fully myeloablative CR, since all 7 patients who received this treatment had donor granulocytes 10 years or more after HSCT versus just 1 of the 10 who had undergone a partially myeloablative CR (busulphan 8 mg/kg, Cy 200 mg/kg) and 4 of 14 who had not undergone a CR at all (P Ͻ .001; Figure  2B ). The latter 2 groups did not differ statistically (P ϭ .38). Interestingly, all 7 patients having received a fully myeloablative CR belong to group 1A (ie, individuals with detectable TREC ϩ naive T cells; Table 1 ; Figure 2C ). In contrast, only 13 of the 24 patients who underwent only partially myeloablative CR or no CR whatsoever had detectable TREC ϩ cells in their blood. Patient status in terms of myeloablative CR versus partially myeloablative CR had no influence on TREC ϩ cell counts (P ϭ .97).
Factors potentially influencing the persistence of TREC ؉ naive T cells
We analyzed several pre-/post-HSCT parameters in an attempt to identify factors influencing the persistence of donor-derived TREC ϩ / naive T cells. It has been shown that SCID patients who receive transplants during the neonatal period exhibit a higher survival rate and a faster T-cell reconstitution than those who received a transplant later. 17 We therefore compared the patients' median age at transplantation with their status in terms of the presence or absence of detectable TREC ϩ T cells (6.5 and 6 months, respectively) but did not find a statistically significant difference. By considering only patients who did not receive a fully myeloablative CR, there was also no detectable difference (data not shown). Equally, the occurrence of either acute and/or chronic GvHD had no influence (data not shown).
The post-HSCT time interval did not significantly influence TREC level determination, since the follow-up period of TREC ϩ patients lacking donor myeloid chimerism (median, 13 years) was only slightly shorter than that of TREC Ϫ patients (median, 16 years).
TREC levels and SCID diagnosis
We next sought to determine whether the presence of NK cells prior to HSCT might influence the persistence of TREC ϩ naive T cells. In fact, no difference between TREC levels in NK Ϫ SCID patients who received transplants (n ϭ 14) versus NK ϩ patients who received transplants (n ϭ 17) was observed (P ϭ .4). Equally, no difference was found when considering patients who received a haploidentical HSC transplant without myeloablative CR, a setting in which host NK cells could reduce donor cell engraftment (data not shown; P ϭ .4). When analyzing data from patients who did not undergo a fully myeloablative CR (n ϭ 24), we found that TREC ϩ cells were detected in 9 of 11 patients with a ␥c deficiency SCID versus only 4 of 13 ␥c ϩ SCID individuals (P ϭ .06; Figure  2D ). It is particularly striking to note that 8 of the 9 SCID patients who exhibited TREC ϩ T cells without detectable myeloid chimerism had a ␥c deficiency (group 1B), whereas only 2 of the 11 individuals in group 2 lacking TREC ϩ cells and host myeloid cells had a ␥c deficiency (P Ͻ .05). In addition, it is worth noting that although 2 of the 3 patients with JAK-3 deficiency (an immunodeficiency similar to that caused by ␥c deficiency) belong to group 2, they had a few CD31 ϩ CD45RA ϩ CD4 ϩ naive T cells (0.054 ϫ 10 9 / L [54/L] and 0.038 ϫ 10 9 /L [38/L], respectively), unlike the other group 2 patients (Table 1) .
Correlation between the presence of TREC ؉ naive T cells and overall T-cell reconstitution
The presence of TREC ϩ /naive T cells was associated with significantly higher T-cell counts (1.8 ϫ 10 9 /L Ϯ 0.969 ϫ 10 9 /L vs Figure 3A ). Total CD4 ϩ and CD8 ϩ T-cell counts were significantly lower in patients with no detectable TRECs (P Ͻ .001, r ϭ 0.79; P ϭ .02, r ϭ 0.43, respectively; Figure 3B ,C). Lastly, the T-cell population in patients with low TREC ϩ cell counts also displayed a lower mitogeninduced proliferative capacity than those in group 1 (P Ͻ .001, r ϭ 0.68; Figure 3D ), as well as a lower antigen-induced proliferation (even though the difference with group 1 was not statistically significant; P ϭ .82, r ϭ 0.04). However, there was no detectable difference in terms of the frequency of B-cell function reconstitution, as evidenced by IgIV therapy dependence; 7 of the 20 patients with detectable TREC ϩ cells required IgIV therapy compared with 6 of the 11 TREC Ϫ patients ( Table 1) .
Clinical status of patients
Within the group of patients with detectable TREC ϩ cells, 60% (n ϭ 12) did not present any clinical manifestations, whereas 30% had upper respiratory tract infections (URTIs; 15%, n ϭ 3) or chronic warts (15%, n ϭ 3). Two patients had immunologic complications (autoimmune hemolytic anemia in 1 case and chronic pulmonary disease in the other). In the group of patients lacking detectable TREC ϩ cells, 45% (n ϭ 5) did not display any clinical manifestations and 38% (n ϭ 4) had infective complications (URTIs in 2 cases, recurrent pneumonitis in 1 case, and severe chronic warts in the other). Two patients in the latter group suffered from chronic immunopathologic conditions, including hepatitis and colitis.
Discussion
We analyzed T-cell immunity in 31 PID patients between 10 to 27 years after HSCT in order to identify parameters determining the long-term correction of T-cell immunodeficiency. We found that the persistence of naive T cells is (i) positively correlated with overall T-cell reconstitution, (ii) mostly associated with myeloid chimerism, and (iii) possibly influenced by diagnosis. Based on TREC levels and naive CD4 T-cell counts, patients were classified into 2 groups. Patients from the group with a high sjTREC content exhibited higher CD3, CD4, and CD8 T-cell counts and greater lymphocyte proliferation in response to mitogen and tetanus toxoid than those displaying low TREC levels. These differences in T-cell phenotype and functional characteristics can probably be attributed to a persistent thymic output. Patel et al 10 and Sarzotti et al 11 have reported that 10 to 12 years after transplantation in SCID patients, phenotypically naive T-cell and TREC levels fall to very low values and that T-cell diversity decreases concomitantly. Our observation of positive TREC levels in 20 of 31 patients somewhat contrasts with those authors' findings. However, it should be noted that none of patients in the Duke report (Patel et al 10 and Sarzotti et al 11 ) underwent a myeloablative conditioning regimen before transplantation, whereas this was the case for 7 patients in our series. Our results agree in part with those recently published by Borghans et al, 18 indicating that 11 of 19 SCID patients displayed good-quality, long-term T-cell reconstitution after HSCT.
The presence of TREC ϩ T cells was found not to correlate with a better clinical outcome. It should be emphasized, however, that our patient numbers were perhaps too small to provide this sort of evidence. It is also possible that a better, TREC-associated immune status will only translate into clinical consequences following a longer period of time than that monitored here, especially since memory T cells are long lived. This warrants careful follow-up of patients over an extended period of time. TREC ϩ T-cell status was also found not to be associated with B-cell function in patients with host myeloid and B-cell chimerism. It is noteworthy that the partially myeloablative CR (Bu ϭ 8 and Cy ϭ 200) underwent by several of the patients was, in most cases, not sufficient to achieve myeloid/B-cell chimerism, as previously reported. 19 In our series, TREC ϩ cell status correlated strongly with myeloid chimerism. In addition, we found a correlation between the use of a myeloablative conditioning regimen and myeloid chimerism. It should be noted that myeloid donor chimerism was detected in 2 patients who did not undergo conditioning, as has occasionally been reported in nonconditioned HSCT for SCID. 8 Muller et al 9 have reported that intrathymic T-cell maturation kinetics are similar in patients who receive either HLA-identical or haploidentical HSC transplants. Likewise, we did not observe any difference between these 2 types of HSCT in terms of long-term thymic output.
Given the very short lifespan of donor-derived granulocytes, detection of the latter reflects the persistence of donor HSCs. It is thus likely that in this setting, there is a persistent flow of T-cell progenitors capable of differentiating into T cells in the thymus over time. The situation is less clear for patients who have a selective T-cell chimerism, since some (n ϭ 9 of 20) still displayed TREC ϩ cells (subgroup 1B), whereas 11 had no longer detectable TREC ϩ cells 10 to 27 years after HSCT. One cannot completely exclude some bias, since the follow-up period of TREC ϩ patients without donor myeloid chimerism was slightly shorter (13 years) than that of TREC Ϫ patients (16 years). However, it is highly unlikely that this 3-year difference accounts for the overall disparity in TREC counts.
Failure to detect sustained TREC levels could be related to the loss of T-cell progenitors in the absence of donor stem cells. It could also be due to the pre-HSCT absence of thymopoiesis in PID, For personal use only. by on December 29, 2009 . www.bloodjournal.org From as well as a possible post-HSCT lesion caused by infections or GvHD. 8, 17, [20] [21] [22] It is noteworthy that we were able to exclude a role for GvHD in inducing thymic lesions, since the TREC ϩ and TREC Ϫ groups did not differ in terms of GvHD incidence and severity. [23] [24] [25] [26] Age at transplantation was also analyzed, since it has clearly been shown that SCID patients who receive transplants during the first months of life exhibit faster, better T-cell reconstitution, as evidenced by higher numbers of CD3 ϩ and naive T cells and increased mitogen-triggered lymphocyte proliferation during the 3 years following transplantation. 17 The favorable outcome of early transplantation has been attributed to the absence of detrimental effects (due to infections or other comorbid factors) on thymic function. However, in the present study, we did not detect a reliable, age-related factor. A high hematopoietic stem-cell dose has been shown to correlate with better immune reconstitution after HSCT. 27, 28 Whether increased numbers of engrafted stem cells could result in long-term thymic production is, however, unknown. In our study, we were not able to test the correlation between the number of injected CD34 ϩ cells and long-term TREC detection. Of note is the recent observation in mice by Bhattacharya et al 29 indicating that an excess of donor HSCs over a certain threshold cannot further displace the endogenous HSCs from their niches in an unconditioned host, since only some bone marrow niches are available for engraftment.
The relatively poor engraftment in patients with T Ϫ /B Ϫ SCID has been attributed to the presence of NK cells able to mediate donor HSC rejection. 30, 31 In our cohort, however, we did not find any difference in long-term T-cell reconstitution between patients who had NK ϩ and NK Ϫ PID phenotypes. One possible explanation (related to the genetic defect itself and its phenotypic consequences) could be related to the competition in the intrathymic stromal niches between donor progenitors and endogenous, immature, double-negative (DN) thymocytes previously found in certain SCID conditions. This is supported by the data of Prockop et al, 32 who demonstrated that Rag-1-deficient mice exhibit high numbers of DN2/DN3 cells and are refractory to thymic reconstitution following HSCT without conditioning because of competition for thymic niches seeding. In contrast, ␥c-deficient mice (in which DN T cells cannot proliferate) were well reconstituted. Strikingly, all but 1 of our patients with good thymic function (but no myeloid engraftment) displayed a ␥c deficiency. It is therefore possible that the low level of thymic progenitors that characterizes this SCID condition had allowed thymic seeding by a population of very early progenitors (possibly with some self-renewal capacity), thus enabling sustained T-cell differentiation. The assumption is also supported by recent data from Weerkamp et al 33 who isolated a very immature, multilineage progenitor from the human thymus. Whether these CD34 ϩ thymocytes represent true HSCs is still subject to debate, since the cells failed to repopulate nonobese diabetic (NOD)-SCID mice. However, it is possible that the fraction of this population that retains the ability to self-renew is too small to be detected. 33 Thymocyte-derived signals are necessary for maturation of the thymic microenvironment and maintenance of thymic epithelial cell organization. It is possible that occupation of the stromal niches by the DN2/DN3 cells in Rag-1/-2 or Artemis deficiencies prevented full replenishment of thymic tissue by normal precursors able to differentiate and then to provide stromal cells with all the required growth signals derived from the different cell subsets. In this respect, the ␥c deficiency background might be more favorable for maintaining full lymphostromal interactions after transplantation. 34, 35 Further study of larger cohorts of HSCT patients with molecularly characterized T-cell immunodeficiencies is now warranted. Our study nevertheless shows that a combination of factors determines the long-term outcome of T-cell reconstitution following HSCT in SCID patients. In the future, these results could lead to better-adapted approaches to HSCT and/or gene therapy for T-cell-immunodeficient patients. 
Background
We investigated the long-term outcome of gene therapy for severe combined immunodeficiency (SCID) due to the lack of adenosine deaminase (ADA), a fatal disorder of purine metabolism and immunodeficiency.
Methods
We infused autologous CD34+ bone marrow cells transduced with a retroviral vector containing the ADA gene into 10 children with SCID due to ADA deficiency who lacked an HLA-identical sibling donor, after nonmyeloablative conditioning with busulfan. Enzyme-replacement therapy was not given after infusion of the cells.
Results
All patients are alive after a median follow-up of 4.0 years (range, 1.8 to 8.0). Transduced hematopoietic stem cells have stably engrafted and differentiated into myeloid cells containing ADA (mean range at 1 year in bone marrow lineages, 3.5 to 8.9%) and lymphoid cells (mean range in peripheral blood, 52.4 to 88.0%). Eight patients do not require enzyme-replacement therapy, their blood cells continue to express ADA, and they have no signs of defective detoxification of purine metabolites. Nine patients had immune reconstitution with increases in T-cell counts (median count at 3 years, 1.07×10 9 per liter) and normalization of T-cell function. In the five patients in whom intravenous immune globulin replacement was discontinued, antigenspecific antibody responses were elicited after exposure to vaccines or viral antigens. Effective protection against infections and improvement in physical development made a normal lifestyle possible. Serious adverse events included prolonged neutropenia (in two patients), hypertension (in one), central-venous-catheter-related infections (in two), Epstein-Barr virus reactivation (in one), and autoimmune hepatitis (in one).
T 448 A denosine deaminase (ada) deficiency is a fatal autosomal recessive form of severe combined immunodeficiency (SCID), of which failure to thrive, impaired immune responses, and recurrent infections are characteristics. 1,2 Toxic levels of purine metabolites (adenosine and adenine deoxyribonucleo tides) due to the deficiency of ADA can cause hepatic, skeletal, neurologic, and behavioral alter ations 1,3,4 and sensorineural deafness. 5 A hemato poietic stem-cell transplant from an HLA-identical sibling, the treatment of choice, is available for only a minority of patients [6] [7] [8] ; the use of alternative donors is associated with a high risk of death or lack of engraftment. 1, 6 Administration of polyethylene glycolmodified bovine ADA (PEG-ADA) corrects the metabolic alterations and improves the clinical condition of patients 2,9 but often fails to sustain correction of the immuno deficiency 10, 11 ; its use is limited by neutralizing antibodies against the bovine enzyme, autoimmunity, and the high cost of lifelong therapy. 1 Gene therapy is effective in patients with Xlinked SCID, 12 but its use has been hampered by the development of T-cell leukemia due to insertional mutagenesis caused by the retroviral vector. 13, 14 Pilot trials have shown the safety and feasibility of gene therapy in patients with SCID due to ADA deficiency, 15-17 but all patients required maintenance with PEG-ADA, and the ADAtransduced stem cells were unable to reconstitute the recipient's immune system. We previously described two patients with ADA deficiency in whom nonmyeloablative conditioning allowed for substantial correction of the metabolic and immune defects 1 year after gene therapy. 18 Here, we describe the long-term outcome of these two children and results in eight additional patients who were treated with nonmyeloablative conditioning followed by infusion of autologous CD34+ cells from bone marrow that had been transduced with a viral vector carrying the ADA gene.
Me thods
Patients
Patients were enrolled from July 2000 through September 2006 in one of three phase 1-2 clinical protocols: one approved by the Hadassah University Hospital Ethics Committee and Israeli National Regulatory Authorities, and two approved by the San Raffaele Scientific Institute's Ethics Committee and the Italian National Regulatory Authorities (Table 1) . Children with SCID due to ADA deficiency who lacked a healthy HLA-identical sibling were eligible for enrollment. In addition, patients who had been treated with PEG-ADA for at least 6 months were eligible in case of inefficacy, defined by immunologic measurements or as intolerance, allergic reaction, or autoimmunity.
The Italian Telethon Foundation received, from the European Medicines Agency, an orphan-drug designation for ADA vector-transduced CD34+ cells (EMEA/OD/053/05). The parents of all patients provided written informed consent for experimental treatment. The two Italian clinical trials are registered in the cell and gene-therapy database of the Italian Istituto Superiore di Sanità, which has required patient-by-patient authorization as of the end of October 2002.
Gene Therapy
Before gene therapy, a central venous catheter was implanted, and bone marrow specimens were obtained and cryopreserved for possible later use. On day 4 before gene therapy, autologous bone marrow specimens were again harvested under general anesthesia; mononuclear cells were isolated by means of density gradients, and CD34+ cells were purified with the use of immunomagnetic beads (CliniMACS, Miltenyi). CD34+ cells were stimulated with cytokines (fms-related tyrosine kinase 3 ligand, KIT ligand, thrombopoietin, and interleukin-3) and transduced with the retroviral vector (GIADAl) based on the Moloney murine leukemia virus carrying the human ADA gene. 18 Supernatant production, cell isolation, and transduction were performed at MolMed according to current Good Manufacturing Practices. Nonmyeloablative conditioning involving the intravenous (or oral, in Patient 2) administration of 2 mg per kilogram per day of busulfan (Busilvex, Pierre Fabre) was performed on days 3 and 2 before gene therapy. Gene therapy consisted of the infusion of CD34+ marrow cells that had been transduced with the ADA-containing vector. 18 
Laboratory Studies
Blood and marrow samples were obtained from patients with SCID due to ADA deficiency, and blood samples were obtained from healthy children and adults as controls, with approval from the San Raffaele Scientific Institute's Ethics Committee and the Hadassah University Hospital Ethics Committee, according to standard ethical procedures. The Supplementary Appendix (available with the full text of this article at NEJM.org) describes measurements of cell subgroups, frequencies of transduced cells, results of flow cytometry, in vitro T-cell responses, antibodies generated after immunization, 19 and ADA activity in cell lysates. 20 
Safety
Adverse events were recorded and reported according to Good Clinical Practice, and were updated as of August 31, 2008 . Patients were monitored through clinical examination, imaging, and hematologic, immunologic, biochemical, and molecular tests, which included testing for replication-competent retrovirus.
Statistical Analysis
Mean or median values are reported, as appropriate. Clinical follow-up (including safety) data were updated as of August 31, 2008 ; analyses regarding molecular, biochemical, and immunologic variables were performed on data as of November 2007. Comparisons between values at various time points and between values for different variables at the same time point were performed by means of the Wilcoxon signed-rank test for paired data (two-tailed tests). The rates of infection (events per person-month of observation) and days of hospitalization were evaluated before gene therapy (from birth) and after therapy (from 4 months after gene therapy onward, to exclude an initial period of procedure-related hospitalization). The degree of correlation was expressed by means of Pearson's correlation coefficient. The data for Patient 2 were evaluated for efficacy until PEG-ADA was introduced at 4.5 years after gene therapy, whereas the data for Patient 8 were evaluated for safety only because PEG-ADA was reintroduced 0.4 year after gene therapy.
R esult s
Ten patients with SCID due to ADA deficiency who had early-onset manifestations (median, 2 months of age) underwent ADA gene therapy at a median age of 1.7 years (range, 0.6 to 5.6) ( Table 1 ). This disorder was diagnosed at birth in one patient, a bone marrow transplant from a mismatched related donor had failed in four patients, and six patients had received PEG-ADA for more than 6 months, with an inadequate response. PEG-ADA was discontinued 3 weeks before gene therapy, to favor the growth of ADA-transduced cells. Patients underwent nonmyeloablative preconditioning with busulfan (total dose, 4 mg per kilogram of body transduced colony-forming units) ( Table 1) . In seven patients, absolute neutrophil counts were less than 0.5×10 9 per liter for more than 1 day after receipt of busulfan, and the duration of neutropenia was related to the area under the concentration-time curve of busulfan (r = 0.65) ( Table 1 and Fig. 1 in the Supplementary Appendix). In two patients, neutropenia lasted over 30 days (Table 2) Table 2) . None of the patients received an allogeneic transplant after gene therapy.
Safety
There were no adverse events that could be attributed to the ADA-transduced cells. A mild and transient increase in liver enzyme levels was detected in four patients within 2 to 3 weeks after treatment. At present, data from a median duration of follow-up of 4.0 years are available for the 10 patients, and no events suggestive of leukemic transformation have been seen. Moreover, no abnormal expansion or clonal outgrowth was detected in immunologic and molecular studies ( Fig. 2A in the Supplementary Appendix). 21 Serious adverse events included two cases of prolonged neutropenia, one of hypertension, three of central-venouscatheter-related infection, one case of Epstein-Barr virus reactivation, which resolved after preemptive therapy with one dose of anti-CD20 monoclonal antibody, and one case of autoimmune hepatitis (Table 2 ). Patient 8, who had recurrent autoimmune hemolytic anemia and the macrophage activation syndrome and had received corticosteroids for 2 years before gene therapy, had three episodes of autoimmune thrombocytopenia, requiring long-term corticosteroid administration, reintroduction of PEG-ADA approximately 5 months after gene therapy, and treatment with anti-CD20.
Engraftment of Vector in Multiple Cell Lineages
ADA-transduced CD34+ cells and their progeny were found in purified marrow ( Fig. 1 ) and blood (Fig. 2) (Fig. 1) . In peripheral-blood specimens at 1 year, the mean frequencies of transduced T cells, B cells, and natural killer cells were 88.0%, 52.4%, and 59.2%, respectively (P = 0.004 for each comparison with granulocytes) ( Fig. 2A through 2D ). In the B-cell lineage, the proportion of vector-positive B cells was significantly higher in the blood than in the bone marrow (P = 0.004). The frequency of vector-positive CD34+ cells at 1 year after gene therapy correlated with the proportion of transduced colony-forming units (r = 0.60) and vector copy number in CD34+ cells (r = 0.75). Moreover, the patients who received a dose of more than 8×10 6 of CD34+ cells per kilogram ( 453 (4.3% vs. 0.6%) at 1 year. ADA-transduced cells persisted in all hematopoietic lineages, including mature granulocytes, through the last evaluation ( Fig. 1 and 2 ).
ADA Expression and Purine Metabolism
The presence of ADA was documented through detection of its enzymatic activity in blood mononuclear cells (Fig. 2E) , marrow mononuclear cells (data not shown), T cells, 23 and red cells and was confirmed through flow cytometry of T and B cells, and monocytes ( 454 cells, 0.35 vs. 0.06 μmol per hour per milliliter; P = 0.004 for both tests), which corresponded to 33.6% and 1.9% of median levels in controls, respectively ( Fig. 2E and data not shown) . The ADA activity in white cells and red cells resulted in a significant reduction of toxic levels of purine metabolites (deoxyadenosine nucleotides) in red cells at 1 year as compared with levels at diagnosis in the same patients (P = 0.004) (Fig. 2F) . With the exception of Patient 2, deoxyadenosine nucleotide levels remained low throughout the follow-up period in all patients who were not receiving PEG-ADA.
Immune Reconstitution
After administration of the ADA vector, there was a progressive increase in T-cell counts, which reached maximum levels at 1 to 3 years (Fig. 3A) .
In children who had been treated with PEG-ADA, the increase occurred after a transient reduction following the discontinuation of enzyme-replacement therapy (Fig. 3A) . As compared with values before gene therapy, the median CD3+ T-cell count was 0.51×10 9 per liter at 1 year of follow-up and 1.07×10 9 per liter at 3 years (P = 0.004 and P = 0.03, respectively) (Fig. 3B) . Median levels of CD4+ T cells and CD8+ T cells 3 years after gene therapy were 0.52×10 9 per liter and 0.47×10 9 per liter, respectively (P = 0.03 for both comparisons with baseline values). According to the most recent follow-up data available for patients not receiving PEG-ADA, T-cell counts were above the lower limits of normal 24 in five patients (Table 3) . T-cell counts did not increase in Patient 2, despite treatment with PEG-ADA (Fig. 3A ). An increase of more than one log 10 unit in the median numbers of circulating naive CD4+CD45RA+ cells and T-cellreceptor excision circles (a marker of recent emigrants from the thymus) in circulating T cells (P = 0.06 and P = 0.03, respectively, for the comparison for 3 years vs. baseline) (Fig. 3 in the Supplementary Appendix) indicated restoration of thymic activity. Remarkably, thymic activity was restored after gene therapy in Patient 6, the oldest subject, who had no detectable T-cellreceptor excision circle at 5.5 years of age while receiving PEG-ADA.
Levels of natural killer cells were significantly increased at 3 years as compared with baseline (P = 0.03) (Fig. 3B ) and displayed normal cytotoxic activity against K562 cells. Proliferative responses of T cells against mitogens (anti-CD3 monoclonal antibody and phytohemagglutinin) were normal by 6 to 12 months of follow-up in all patients and remained normal during the followup period (Fig. 3C) . Proliferative responses to alloantigens, Candida albicans, and tetanus toxoid were also observed in most patients (Table 3) .
The T-cell-receptor repertoire was polyclonal, as ascertained by means of flow cytometry ( are also shown: the top shaded areas represent the median values for healthy controls 2 to 5 years of age (dotted upper boundaries) and 5 to 10 years of age (dashed lower boundaries), and the bottom shaded areas, the 5th percentiles (pct) for those age classes, respectively. 24 For additional comparisons in Panel B, the reference values for CD8+ T cells in healthy controls for both age classes are 0.8×10 9 per liter for the median and 0.3×10 9 per liter for the 5th percentile. Panel B (right side) also shows the median cell counts for CD19+ B cells and CD56+/CD16+ natural killer cells at various time points. The 5th percentile for healthy controls 2 to 5 years of age and 5 to 10 years is shown for B cells (blue broken line; same value for both age classes) and natural killer cells (purple broken upper line, value for 2 to 5 years of age; purple broken lower line, value for 5 to 10 years of age). The median values for healthy controls in the two age classes are 0.8×10 9 to 0.5×10 9 per liter for B cells and 0.4×10 9 to 0.3×10 9 per liter for natural killer cells. Panel C shows data for the in vitro proliferative responses to anti-CD3 monoclonal antibody (on a log 10 scale, left side) and to phytohemagglutinin (on a linear scale, right side). The data are expressed as counts per minute (cpm) in ADA-deficient patients (for nine study patients before gene therapy and 6 months and 1 year afterward, for seven patients 2 years afterward, and for five patients 3 years afterward) and in 114 healthy controls. For the boxand-whisker plots, the box contains the data points that fall between the first and third quartiles, the horizontal line indicates the median, the diamond indicates the mean, and the brackets delineate 1.5 times the interquartile range (with data outside this range shown as individual points). The dashed horizontal line represents the 5th percentile for healthy controls (children and adults). receptor Vβ families after gene therapy were polyclonal, according to spectratyping analyses. In three patients previously given PEG-ADA, the proportion of Vβ T-cell receptors displaying a polyclonal profile increased from 18±10% to 79±9% after gene therapy.
B-cell counts increased progressively after gene therapy (Fig. 3B) , and as of the most recent follow-up visit, the counts were normal in four patients (Table 3 ). The proportion of CD27+ memory B cells was similar in patients who underwent gene therapy and age-matched controls, with a polyclonal immunoglobulin-gene rearrangement in both groups (data not shown). Serum levels of IgA and IgM reached normal values in the majority of patients (Table 3) , and serum IgG levels were within the normal range in five patients after discontinuation of intravenous immune globulin supplementation. In these five patients, antibodies against toxoid, conjugated or bacterial polysaccharide antigens, or measles, and rubella were detectable after immunization with these antigens (Table 3) .
Clinical Outcome
All 10 patients are alive. The nine patients who could be evaluated for efficacy (all but Patient 8) are well, with the duration of follow-up ranging from 1.8 to 8.0 years ( Table 2) . Patients 1 through 6 go to school regularly or, if of preschool age, have normal social relationships with other children and parents. All but two patients (Patients 1 and 9) were below the reference, the 5th percentile, in height and weight before gene therapy; at 1 year after gene therapy, their median weight increased from the 1.7th to the 13.6th percentile and the median height increased from the 3.4th to the 10.9th percentile (Fig. 4 in the Supplementary Appendix).
The rate of severe infections, expressed as the number of events per 10 person-months of observation, decreased from 0.93 before gene therapy to 0.13 after gene therapy. The median number of hospitalization days dropped from 45 before gene therapy to 2 after therapy. Three of the six infections were due to catheter-related bacteremia (Table 2) ; no life-threatening opportunistic infections have occurred. Most patients had abnormalities in neuropsychomotor development at onset that improved during the follow-up period. Three patients had hearing deficits before gene therapy that persisted afterward.
Discussion
We found that treatment of SCID due to ADA deficiency by means of nonmyeloablative chemotherapy followed by an infusion of autologous hematopoietic stem cells that had been transduced with a retroviral vector bearing the ADA gene is not associated with adverse events during a median follow-up period of 4.0 years. The treatment supplies the patient with hematopoietic stem cells that pass a functional ADA gene to all their progeny. Of the 10 patients with SCID due to ADA deficiency who were treated in this manner, there was restoration of immune function and protection against severe infection in 9. The sustained expression of ADA in multiple hematopoietic-cell lineages allowed for the detoxification of purine metabolites and improvement in the patients' physical development.
The mortality rates in ADA-deficient patients who receive transplants from unrelated and haploidentical donors after cytoreduction are 37% and 70%, respectively. 6,25 Transplantation without conditioning, involving marrow from a parent, is successful for most types of SCID, 7,26 but only half of ADA-deficient patients with SCID have sustained donor engraftment. Our protocol, in contrast, affords excellent survival without serious complications, such as graft-versus-host dis- ease. 1, 6, 8 In addition, gene therapy is suitable for older children with SCID due to ADA deficiency, who have a higher risk of failure and complications after transplantation. 6, 26 Patients from whom a small number of bone marrow cells were harvested or who have preexisting chromosomal alterations in the marrow 27 may not be candidates for gene therapy. Enzyme-replacement therapy is effective in most patients with ADA deficiency 2 but often fails to sustain lymphocyte counts and T-cell function. 10, 11, 25 We found that ADA gene therapy improves immune function in patients who had insufficient immune reconstitution during PEG-ADA therapy. Taken together, these results indicate that the intracellular expression of ADA after gene transfer is superior to extracellular detoxification by PEG-ADA in permitting the maturation and survival of functional lymphocytes.
The use of nonmyeloablative conditioning 18,28 and withdrawal of PEG-ADA were crucial factors in the successful outcome of our trial. Earlier genetherapy trials for SCID due to ADA deficiency, [15] [16] [17] which did not include conditioning regimens, were hampered by limited engraftment and immune reconstitution. Our data show that nonmyeloablative conditioning allows for the engraftment of transduced stem cells. Conditioning with busulfan was also used (at a dose of 8 mg per kilogram) in a gene-therapy protocol for treating chronic granulomatous disease, 29 resulting in the engraftment of 10 to 15% of transduced granulocytes. Another gene-therapy trial for SCID due to ADA deficiency used melphalan for conditioning and achieved metabolic and T-cell reconstitution, but only 0.1% of granulocytes carried the ADA gene. 22 In our trial, the number of infused CD34+ cells and the efficiency of in vitro gene transfer were also critical.
Previous gene-therapy studies with mature lymphocytes 30 or hematopoietic stem cells 17, 18, 22 indicated that enzyme-replacement therapy inhibited the outgrowth of ADA-transduced cells. Our study supports the notion that a toxic environment caused by high levels of purine metabolites at the time of stem-cell engraftment is advantageous in supporting the differential expansion of gene-corrected cells, especially in lymphoid lineages.
Gene therapy restored normal immune function in five patients and resulted in significant improvement in lymphocyte counts and functions in the other five patients, leading to protection from infectious complications. The reconstitution of lymphocyte levels was considerably slower in comparison to recovery after a bone marrow transplant including T cells from an HLA-identical donor. This difference is most likely due to the time required for the differentiation of T cells from purified, vector-containing stem cells. We believe that early intervention with gene therapy in patients with SCID due to ADA deficiency can reduce the risk of thymic involution and that optimization of the conditioning procedure will improve engraftment and immune recovery.
Gene therapy has been shown to benefit patients with X-linked SCID or chronic granulomatous disease, but the results were seriously limited by the development of leukemic proliferation (in 5 of 19 patients with X-linked SCID 31, 32 ) and clonal expansion of myeloid cells (in 2 patients with chronic granulomatous disease 29 ). These complications were associated with retroviralvector insertions near cellular proto-oncogenes. Our long-term follow-up and the experience in other trials of patients with SCID due to ADA deficiency 17,22,33,34 did not reveal such complications. This is consistent with the polyclonal pattern of vector integration and T-cell repertoire, and the lack of in vivo skewing for potentially dangerous insertions. 21 (See the Supplementary Appendix for further discussion of this complication of gene therapy in SCID.)
In conclusion, gene therapy with nonmyeloablative conditioning is an option to be considered for all patients with SCID due to ADA deficiency who lack an HLA-identical sibling donor. Our study suggests that gene therapy in combination with appropriate conditioning regimens could be successfully extended to the treatment of other congenital diseases involving the hematopoietic system. 
Laboratory studies
Frequency of transduced cells. Cell subpopulations were purified using antibody-coated microbeads or FACS sorting. 1 The frequency of transduced cells and vector copy number were determined on genomic DNA by quantitative PCR analysis for NeoR vector sequences, normalized for DNA content.
Immunological studies. All immunostaining and flow cytometry were performed as described. 2 In vitro T-cell responses to mitogens and antigens were measured by thymidine incorporation in proliferative assays. 2 Biochemical studies. ADA activity in cell lysates was measured by an adenosine to inosine conversion assay, followed by high-performance-capillary-electrophoresis (HPCE). 10 Total adenine ribo-(AXP) and deoxyribonucleotides (dAXP) in erythrocytes were measured by HPCE.
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Supplementary Results
Six severe infections requiring hospitalization were recorded in five patients. The patients were hospitalized -for 2, 5, 6, 6, and 21 days (total days for two episodes), respectively (see also Table   2 , main manuscript). on PEG-ADA and suffering from recurrent infections and persistent autoimmunity requiring chronic steroid treatment.
Supplementary Discussion
Busulfan was included in our protocol because of its potent effects on primitive hematopoietic progenitors and the lack of organ toxicity at reduced doses in nonmyeloablative regimens for hematopoietic stem cell (HSC) transplant. 2, 11 Studies in non human primates indeed showed that low dose busulfan provides a strong competitive advantage for the survival and proliferation of transplanted HSC during suppression of endogenous hematopoiesis.
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In addition to the points discussed in the main text, we cannot exclude that the slower kinetic of Tcell reconstitution is due to a lower number of "true" gene corrected repopulating HSC in the infused autologous graft, as compared to unmanipulated HSC from a normal donor in the context of an allogeneic bone marrow transplant.
Several possible explanations may account for the differences between the ADA-SCID and the Xlinked SCID gene therapy trials 13, 14 . First, ADA is a constitutively expressed enzyme of purine metabolism which does not need regulation and favors survival of cells rescued by gene therapy.
The IL2RG is a signal transducing receptor chain which is upregulated upon T-cell activation and induces T-cell proliferation when combined with the receptors of one of the six different cytokines Weight Height percentiles
